Bristol Myesrs Squibb & Exscientia In $1.2 billion Artificial Intelligence Drug Discovery Deal

Bristol Myers Squibb (BMS) has announced a new collaboration agreement with Exscientia to use artificial intelligence (AI) to discovery drug candidates across a number of therapeutic areas. The collaboration will leverage Exscientia‚Äôs AI technology to accelerate the discovery of small molecule therapeutic drug candidates in multiple therapeutic areas, including oncology and immunology. As part of…